Navigating Second-Line Endocrine Options in Breast Cancer

By News Health
1 hour Ago

(MedPage Today) — The second-line endocrine therapy landscape in hormone receptor (HR)-positive, HER2-negative advanced breast cancer is becoming increasingly complex, with decisions now shaped by ESR1 and PIK3CA mutations, CDK4/6 inhibitor exposure…

Source link : https://www.medpagetoday.com/meetingcoverage/esmovideopearls/118577

Author :

Publish date : 2025-11-18 17:20:00

Copyright for syndicated content belongs to the linked Source.

Categories: Health News

Related Content

YesRx: Michigan Program Turns Cancer Drug Waste Into Hope

Medicine Needs a 'Millennialist' Sub-Specialty

When Ditching Dialysis Makes Sense for Older Adults

South Carolina Lawmakers Look at the Most Restrictive Abortion Bill in the U.S.

Study Offers Reassurance for Moms-to-Be With Spondyloarthritis

'Push Back on Orthodoxy,' Dr. Oz Tells AMA's House of Delegates